Every Form 4 that GLOBUS MEDICAL INC (GMED) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GMED and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GMED filings page.
GLOBUS MEDICAL INC (GMED) director Stephen T. Zarrilli reported an option exercise and same-day stock sale. He exercised 25,000 stock options for Class A Common Stock at an exercise price of $53.27 per share, then sold 25,000 shares of Class A Common Stock at a weighted average price of $87.0386 per share in multiple transactions. The options exercised were fully vested and, after the exercise, the reported option position in this grant was 0 shares.
Globus Medical Inc. director David D. Davidar reported a bona fide gift of 2,500 shares of Class A Common Stock on July 27, 2026, at $0.00 per share. After the gift, he directly holds 507,675 shares and has indirect ownership of 165,967 shares held in the Davidar Family Irrevocable Trust U/A 8/6/09 for the benefit of his spouse and children, with his spouse serving as trustee. The filing indicates this transaction was not made under a Rule 10b5-1 trading plan.
Globus Medical director David D. Davidar reported an exercise-and-sell transaction in Class A common stock. He exercised stock options for 25,000 shares at $26.27 per share and sold 25,000 shares in an open-market transaction at a weighted average price of $80.7629 per share.
Following these moves, Davidar directly holds 510,175 shares of Class A common stock. In addition, a family irrevocable trust established on August 6, 2009 holds 165,967 shares for the benefit of his spouse and children, with his spouse serving as trustee.
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options were granted on January 30, 2017 and were fully vested at exercise. Following the transaction, she directly owns 40,384 shares, and this filing shows no related share sales.
Globus Medical EVP and General Counsel Kelly Huller reported option exercises and a share sale involving Class A common stock. On February 25, 2026, Huller exercised stock options for 20,000 shares granted on January 22, 2019, which are described as fully vested.
The option exercise was reported at a price of $43.58 per share, resulting in direct ownership of 20,000 shares of Class A common stock. That same day, Huller sold 20,000 shares of Class A common stock at $94.50 per share, leaving no shares reported as directly owned after the sale.
The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated November 12, 2025, indicating the sale was pre‑scheduled rather than newly decided at the time of the transaction.
Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale. On February 12, 2026, she exercised stock options for 10,000 Class A shares at $45.64 per share, converting a fully vested grant from February 2018.
The same day, she sold 10,000 Class A shares at $87.67 per share in an open-market transaction, leaving her with 0 directly owned shares and 0 remaining options from this grant. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated November 12, 2025.
Globus Medical director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock. The options carry an exercise price of $94.15 per share and were granted as a derivative equity award.
According to the filing, these options were granted on January 21, 2026, will vest on January 1, 2027, and expire on January 21, 2036. After this grant, Norwalk beneficially owns 15,000 derivative securities directly, reflecting a standard director compensation award rather than an open-market transaction.
Globus Medical Inc. reported a new stock option grant to its President and CEO, Keith W. Pfeil. On January 21, 2026, Pfeil received stock options giving him the right to buy 100,000 shares of Class A common stock at an exercise price of $94.15 per share. The options were granted at no cost to him as compensation and expire on January 21, 2036.
The award vests over four years, with one-quarter of the options vesting on January 1, 2027 and the remaining options vesting in equal monthly installments (1/48 of the total) each month thereafter. All 100,000 options are reported as held directly by Pfeil following this grant.
Globus Medical Senior Vice President and CFO Kyle Kline received a grant of 30,000 stock options to buy Class A common stock at an exercise price of $94.15 per share. The options were granted on January 21, 2026 and were reported as directly owned by Kline. They vest over a four-year period, with one-quarter vesting on January 1, 2027 and the remaining three-quarters vesting in equal monthly installments of 1/48 of the grant each month thereafter, ending on the stated expiration date of January 21, 2036.
Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options. On January 21, 2026, he was awarded 100,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options themselves granted at a cost of $0.
The options vest over four years, with one quarter vesting on January 1, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years. After this grant, he beneficially owns 100,000 derivative securities directly in the form of these options.
Globus Medical Inc. director Douglas Robert Andrew received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The filing shows these options were granted for no cash payment at grant.
According to the disclosure, the options will vest on January 1, 2027, meaning they become exercisable on that date, and they expire on January 21, 2036 if not exercised. Following this grant, he beneficially owns 15,000 derivative securities directly in the form of these options.
Globus Medical director Dan Lemaitre received a new stock option grant. On January 21, 2026, he was awarded options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share, with no cost reported for the options themselves. These options will vest on January 1, 2027 and expire on January 21, 2036. Following this grant, Lemaitre beneficially owns 15,000 derivative securities directly through this option award.
Globus Medical director Ann D. Rhoads received a new stock option award. On January 21, 2026, she was granted options to purchase 15,000 shares of Globus Medical Class A common stock at an exercise price of $94.15 per share. The options were granted at a price of $0 for the derivative itself and are held directly. They will vest on January 1, 2027 and are scheduled to expire on January 21, 2036, giving her a long-term incentive tied to the company’s share performance.
Globus Medical Inc. director James R. Tobin received a grant of stock options on January 21, 2026. The award covers 15,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with no purchase price for receiving the options themselves.
According to the filing, these options will vest on January 1, 2027 and expire on January 21, 2036 if not exercised earlier. After this grant, Tobin holds 15,000 derivative securities directly, all from this option award. This represents routine equity-based compensation that aligns the director’s interests with the company’s long-term share performance.
Globus Medical Inc. filed an insider trading report showing a new stock option grant to director Stephen T. Zarrilli. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The grant was recorded at a price of $0 because it reflects an award, not a purchase in the market. These options are held directly and will vest on January 1, 2027, with an expiration date of January 21, 2036.
Globus Medical Inc. director John A. DeFord reported a grant of stock options linked to the company’s Class A common stock. On January 21, 2026, he received 15,000 stock options with an exercise price of $94.15 per share and no cost at grant. According to the disclosure, these options will vest on January 1, 2027, and DeFord now beneficially owns 15,000 derivative securities directly following this transaction.
Globus Medical Inc. granted stock options to director Dan Wolterman. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. These options were granted at no cost to him and are held as a direct ownership position.
The options will vest on January 1, 2027, meaning they become exercisable on that date and remain outstanding until their expiration on January 21, 2036. Following this grant, Wolterman beneficially owns 15,000 derivative securities in the form of these stock options.
Globus Medical Inc. director David D. Davidar received a stock option grant for 15,000 derivative securities tied to Class A common stock. The options were granted on January 21, 2026 at a conversion or exercise price of $94.15 per share and had no purchase price for the derivative security itself. Following this grant, 15,000 derivative securities are beneficially owned on a direct basis.
The options will vest on January 1, 2027 and are scheduled to expire on January 21, 2036. Each option represents the right to buy one share of Class A common stock, so the grant covers 15,000 underlying shares.
Globus Medical Inc. reported that executive Kelly G. Huller, EVP, General Counsel and Corporate Secretary, received a grant of stock options on January 21, 2026. The award covers 40,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options held directly.
According to the vesting terms, the options vest over four years, with 25% vesting on January 1, 2027, and the remaining options vesting in equal monthly installments of 1/48 each month thereafter. The options have an expiration date of January 21, 2036, giving the executive a long-term incentive tied to the company’s share performance.
Globus Medical Inc. senior vice president and CFO filed an amended insider trading report updating details of a prior stock option exercise and share sale. The amendment clarifies that on December 1, 2025, the officer exercised 4,896 stock options with an exercise price of $63.68 and then sold the underlying 4,896 shares of Class A common stock, rather than 5,000 options as previously reported.
The options relate to a grant made on January 27, 2022, which vests over four years, with one-fourth vesting on January 1, 2023 and the remainder vesting monthly over the following 36 months, and they expire on January 27, 2032. Following the corrected transaction, the officer beneficially owns 104 derivative securities (remaining options) directly.
Globus Medical Senior Vice President and CFO Kyle Kline reported exercising stock options and selling the underlying shares. On January 8, 2026, he exercised 3,594 stock options for Class A common stock at an exercise price of $51.87 per share, receiving 3,594 shares. That same day, he sold 3,594 Class A common shares at a price of $101.10 per share under transaction code "S." After these transactions, he reported 0 shares of Class A common stock directly owned and 3,906 stock options remaining. The sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025, and the options exercised were part of a grant from March 14, 2024 that vests over four years.
Globus Medical director reports preset stock sale
Globus Medical director Leslie V. Norwalk reported selling 2,000 shares of the company’s Class A common stock on January 8, 2026 at a price of $101.10 per share. After this transaction, Norwalk beneficially owned 10,419 Class A shares, all held directly. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was put in place on September 12, 2025, indicating the trades were pre-arranged rather than decided at the time of sale.
Globus Medical Inc. director reports equity gift
A director of Globus Medical Inc. reported a transaction in the company’s Class A common stock dated 01/02/2025 with transaction code "G", indicating a gift. The filing shows 6,100 shares of Class A common stock were disposed of at a stated price of $0 as part of this gift transaction.
Following the reported transaction, the director beneficially owns 510,175 shares of Class A common stock directly. In addition, 165,967 shares are held indirectly through the Davidar Family Irrevocable Trust U/A 8/6/09, which is a trust for the benefit of the reporting person’s spouse and children, with the spouse serving as trustee.
Globus Medical Inc. director reported selling 4,000 shares of Class A common stock on 12/12/2025 at $88.85 per share in a transaction carried out under a Rule 10b5-1 trading plan dated September 12, 2025.
Following this planned sale, the director directly owns 12,419 shares of Globus Medical stock, as disclosed in the Form 4 filing.
Globus Medical's executive chairman, who is also a director and 10% owner, reported exercising stock options for 34,375 shares of Class A common stock at $25.52 per share on 12/08/2025. Following this option exercise, he directly owns 60,417 shares of Globus Medical Class A common stock.
The derivative position was a stock option giving the right to buy 34,375 Class A shares at an exercise price of $25.52. These options were originally granted on January 25, 2016, are fully vested, and relate to 34,375 underlying Class A shares with an expiration date of 01/25/2026.
Globus Medical reported insider activity by its Senior Vice President and Chief Financial Officer. On December 1, 2025, the executive exercised multiple stock options for Class A common stock, acquiring 3,646 shares at $53.14, 5,000 shares at $56.43, 5,000 shares at $64.44, and 4,896 shares at $63.68. The same day, the executive sold 18,542 shares at $90 per share, leaving no directly held Class A common stock after the reported transactions.
The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025. The options exercised were previously granted awards that vest over four years or are already fully vested, with expiration dates ranging from 2031 to 2034.
Globus Medical Inc. insider activity: A senior vice president who also serves as general counsel and corporate secretary reported an options exercise and stock sale in Class A common stock. On 11/25/2025, the executive exercised stock options covering 7,500 shares at an exercise price of $25.96 per share, increasing direct ownership of common stock to 7,500 shares.
On the same date, the executive sold 7,500 shares of Class A common stock at $90 per share under a Rule 10b5-1 trading plan dated December 4, 2024. Following these transactions, the reporting person disclosed beneficial ownership of 0 shares of Class A common stock and 0 related stock options.
Globus Medical Inc. (GMED) director reported an insider transaction involving company Class A common stock. On 11/12/2025, the reporting person exercised 25,000 stock options at an exercise price of $25.52 per share and on the same date sold 25,000 shares of Class A common stock at a weighted average price of $86.0002 per share. After these transactions, the director directly beneficially owns 516,275 shares of Class A common stock and indirectly beneficially owns 165,967 shares held in a family trust. The reported options were granted on January 25, 2016 and are fully vested.
Globus Medical (GMED) reported an insider transaction by a director. On 11/11/2025, the director exercised stock options for 25,000 Class A shares at $44.14 and then sold 25,000 Class A shares at a $84.2903 weighted average price.
Following these transactions, the director held 0 shares directly. The options were granted on May 1, 2019, were fully vested, and had an expiration date of 05/01/2029.
Globus Medical (GMED) reported a director’s open‑market sales of Class A common stock. On 11/07/2025, the director sold 8,000 shares at $81, and on 11/10/2025 sold 2,000 shares at $85. These transactions were made under a Rule 10b5‑1 trading plan dated November 8, 2024. Following the reported trades, the director beneficially owned 15,384 shares.